Education
About Us
Working with TipRanks
Follow Us
ProKidney (PROK)
NASDAQ:PROK
PROK Stock Chart & Stats
$1.93
-$0.14(-7.65%)
At close: 4:00 PM EST
$1.93
-$0.14(-7.65%)
Day’s Range― - ―
52-Week Range$0.46 - $7.13
Previous CloseN/A
Volume58.77K
Average Volume (3M)614.15K
Market Cap
$580.56M
Enterprise Value$437.55M
Total Cash (Recent Filing)$270.02M
Total Debt (Recent Filing)$2.96M
Price to Earnings (P/E)―
Beta2.09
Next Earnings
May 08, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding141,545,440
10 Day Avg. Volume628,375
30 Day Avg. Volume614,155
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.00
Price to Sales (P/S)335.98
P/FCF Ratio-2.22
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue489.98
Enterprise Value/Gross Profit-223.92
Enterprise Value/Ebitda-2.95
Forecast
1Y Price Target
$7.33Price Target Upside279.79% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-0.62
Revenue Forecast (FY)$216.67K
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And SafetyPositive prior-phase efficacy signals combined with no reported procedure- or product-related serious adverse events support a credible clinical rationale for the registrational strategy.
Regulatory PathwayPursuit of an FDA-aligned accelerated approval pathway based on the eGFR surrogate endpoint could enable a faster route to a biologics license application and potential commercial launch if surrogate results meet regulatory standards.
Trial Enrollment MomentumStrong patient enrollment in the pivotal trial signals meaningful patient and physician interest, reducing execution risk and supporting timely completion of key study milestones.
Bears Say
Commercial And Investor UncertaintyKeeping the same number of events with fewer total patients increases variability in the confirmatory timeline, heightening uncertainty around commercial rollout and investor expectations.
Confirmatory Trial DurationReducing confirmatory study enrollment while retaining the same event requirement implies the confirmatory analysis will take longer, extending the time to final approval.
Regulatory Outcome RiskRelying on a surrogate eGFR threshold for accelerated approval creates a binary regulatory risk if the trial does not meet the required surrogate endpoint.
ProKidney News
PROK FAQ
What was ProKidney’s price range in the past 12 months?
ProKidney lowest stock price was $0.46 and its highest was $7.13 in the past 12 months.
What is ProKidney’s market cap?
ProKidney’s market cap is $580.56M.
When is ProKidney’s upcoming earnings report date?
ProKidney’s upcoming earnings report date is May 08, 2026 which is in 47 days.
How were ProKidney’s earnings last quarter?
ProKidney released its earnings results on Mar 18, 2026. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.147 by $0.007.
Is ProKidney overvalued?
According to Wall Street analysts ProKidney’s price is currently Undervalued.
Does ProKidney pay dividends?
ProKidney does not currently pay dividends.
What is ProKidney’s EPS estimate?
ProKidney’s EPS estimate is -0.14.
How many shares outstanding does ProKidney have?
ProKidney has 141,545,440 shares outstanding.
What happened to ProKidney’s price movement after its last earnings report?
ProKidney reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.147. Following the earnings report the stock price went down -6.25%.
Which hedge fund is a major shareholder of ProKidney?
Currently, no hedge funds are holding shares in PROK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ProKidney Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$7.33 (279.79% Upside)
$7.33 (279.79% Upside)
Blogger Sentiment
Bullish
PROK Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 528.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 2.2%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Negative
20 days / 200 days
Momentum
104.88%
12-Months-Change
Fundamentals
Return on Equity
10.19%
Trailing 12-Months
Asset Growth
-24.10%
Trailing 12-Months
Company Description
ProKidney
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
PROK Stock 12 Month Forecast
Average Price Target
$7.33
▲(279.79% Upside)
Technical Analysis
Rezolute
―
Urogen Pharma
―
Phathom Pharmaceuticals
―
Relay Therapeutics
―
Nurix Therapeutics
―
Ownership Overview
Currently, No data available
---